{"Q": 1, "answer": "no", "rationale": "'very quickly' modifies a verb ('respond'), not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_7048", "batch_size": 260, "batch_pos": 31, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses factual language without high-potency verbs, metaphors, superlatives, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_7732", "batch_size": 260, "batch_pos": 20, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "\"plans to launch\" and \"could respond\" refer to future actions or capabilities.", "method": "llm_batch", "batch_id": "batch_3_15680", "batch_size": 260, "batch_pos": 8, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_12056", "batch_size": 260, "batch_pos": 258, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports a plan to launch a human trial and ability to respond quickly but does not explicitly link it to public/consumer safety.", "method": "llm_batch", "batch_id": "batch_5_688", "batch_size": 260, "batch_pos": 257, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_6692", "batch_size": 260, "batch_pos": 250, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_3900", "batch_size": 260, "batch_pos": 250, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes planned future capability ('plans to launch a small human trial') and potential future capability ('could respond very quickly') without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_18152", "batch_size": 260, "batch_pos": 208, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
